Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa downgraded Pfizer Inc. (NYSE:PFE) to Neutral from Outperform and set a $27 price target. Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders In another development, Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansio ...

Core Insights - Pfizer Inc. is recognized as a strong investment opportunity by hedge funds, particularly due to its recent FDA developments regarding HYMPAVZI for hemophilia treatment [1][2] Group 1: FDA Developments - The FDA accepted and granted Priority Review for Pfizer's supplemental Biologics License Application for HYMPAVZI, expanding its indication to treat hemophilia A or B patients aged 6 years and older with inhibitors, and pediatric patients without inhibitors [1] - The FDA has set a Prescription Drug User Fee Act action date for Q2 2026, and if approved, HYMPAVZI will offer a once-weekly subcutaneous injection with minimal preparation and no routine lab monitoring required [2] Group 2: Financial Performance - Pfizer reported full-year revenues of $62.6 billion for fiscal 2025, reflecting a 2% year-over-year operational decline, but a 6% operational growth when excluding revenues from Paxlovid and Comirnaty [3] - Fiscal Q4 revenues were $17.6 billion, indicating a 3% year-over-year operational decline [3] Group 3: Company Overview - Pfizer is a global biopharmaceutical company engaged in the manufacturing, development, marketing, and sale of biopharmaceutical products, focusing on wellness, prevention, treatment, and cures in various markets [4]

Pfizer Inc. (NYSE:PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results from its Phase 3 BASIS Study, which evaluates HYMPAVZI for people living with hemophilia A or B with inhibitors. The study included 48 adults and adolescents with severe hemophilia A or B. Patients treated with HYMPAVZI showed a 93% reduction in the annualized bleeding rate (ABR) compared to OD therapy. Management noted that HYMPAVZI is administered only once a week through subcutane ...

Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with inhibitors. Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock The results showed the superiority of HYMPAVZI for the improvement of bleeding outcomes in comparison with on-demand (OD) treatment with bypassing agents, reducing bleeds by 93% in ado ...

Core Viewpoint - Pfizer is attempting to reposition itself after a decline in COVID-related revenues, with a focus on oncology and other therapeutic areas to drive future growth [1][2]. Group 1: Financial Performance - Pfizer's stock has decreased by 19.3% over the past 52 weeks and 9.7% year-to-date, largely due to declining sales of its COVID-19 products Comirnaty and Paxlovid [1]. Group 2: Oncology Portfolio - Pfizer's oncology portfolio is showing significant progress, with a focus on increasing research and development productivity by 2025 [4]. - Braftovi and Mektovi have achieved a 23% year-over-year operating growth in the second quarter, indicating strong momentum in cancer-targeted treatments [4]. - The investigational antibody-drug conjugate Sigvotatug vedotin (SV) is advancing in Phase 3 trials for non-small cell lung cancer (NSCLC), which is projected to reach a market size of $60 billion by 2030 [5]. Group 3: Strategic Collaborations - Pfizer's collaboration with 3SBio provides access to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, in the $55 billion immunotherapy market [5]. Group 4: Hematology and Vaccines - In hematology, HYMPAVZI has shown promising Phase 3b findings, with potential to capture market share in the hemophilia industry, expected to reach $10 billion by 2030 [6]. - Pfizer is nearing the end of its Phase 3 trial for a Lyme disease vaccine and plans to file for approval next year, addressing significant unmet needs in the vaccine market [6].

Group 1: Company Overview - Pfizer Inc. is a global pharmaceutical leader focusing on mRNA vaccines, oncology, immunology, and infectious diseases, with notable recognition for its COVID-19 vaccine collaboration with BioNTech [1][2] - The company is advancing its mRNA vaccine portfolio, recently announcing progress with its LP.8.1-adapted COMIRNATY 2025-2026 formula [1] Group 2: Vaccine Development - In September 2025, Pfizer reported positive Phase 3 topline data showing a fourfold increase in neutralizing antibodies in adults aged 65+ and high-risk adults aged 18–64, supporting FDA approval [2] - The adaptive vaccine targets emerging SARS-CoV-2 sublineages, reinforcing Pfizer's strategic direction to maintain vaccine efficacy amid changing pandemic conditions [2] Group 3: Oncology and Specialty Medicines - Pfizer is advancing oncology and specialty medicines, with combination therapy PADCEV plus KEYTRUDA showing improved survival rates in bladder cancer [3] - The company is also progressing with HYMPAVZI for hemophilia treatment, demonstrating its commitment to high-need therapeutic areas [3] Group 4: Research and Development Focus - Despite facing regulatory challenges and patent litigation over Paxlovid, Pfizer continues to invest in R&D and strategic partnerships [4] - The company's focus on adaptive mRNA technology, AI-driven development, and precision medicine highlights its leadership among biotech innovators [4]

Group 1 - Pfizer Inc. is recognized as a global pharmaceutical leader, advancing innovative medicines and vaccines across various therapeutic areas, including oncology and immunology [1] - The company gained significant attention for its COVID-19 vaccine developed in collaboration with BioNTech, contributing to global pandemic response efforts [1] - Pfizer's recent Phase 3 data for its updated COVID-19 vaccine formula shows a four-fold increase in neutralizing antibody titers in older adults and high-risk populations, supporting FDA approval [2] Group 2 - Pfizer is making strides in oncology, with recent combinations of PADCEV and KEYTRUDA showing improved survival rates for bladder cancer, and XTANDI with leuprolide enhancing outcomes in high-risk prostate cancer [3] - The company is also advancing in hematology with HYMPAVZI, a treatment for hemophilia A or B that significantly reduces bleeding episodes compared to traditional therapies [4] - Pfizer is targeting $4.5 billion in cost savings by the end of 2025, with plans to reinvest in R&D to sustain innovation amid patent expirations [5] Group 3 - Global licensing agreements, such as the deal with 3SBio, are part of Pfizer's strategy to expand its market reach [5]